CAMBRIDGE, Mass. (AP) — Genzyme Corp. said Friday its kidney-disease treatment Renvela was approved for sale in the European Union. The European Commission approved Renvela tablets and powder for use in controlling the serum phosphorus levels of patients with chronic kidney disease. Serum phosphorus is a chemical that helps take energy from food, and when it is not properly filtered by the kidneys, it builds up in the body and can cause calcification of tissues. The approval covers dialysis patients and those who are not on dialysis. Renvela is a newer version of a previous Genzyme drug called Renagel. Renvela tablets were approved for sale in the U.S. in March 2008, but the market approval only covered patients on dialysis. The company is seeking approval for the powdered version of the drug and wants to market them to patients not on dialysis as well.